EUCTR2007-001625-10-ES进行中（未招募）1 期
Estudio abierto y aleatorizado para evaluar la eficacia radiológica y la seguridad de Enbrel® (etanercept) añadido a metotrexato en comparación con el tratamiento habitual en pacientes con artritis reumatoide moderadaAn Open-Label, Randomized Study To Evaluate The Radiographic Efficacy And Safety Of Enbrel™ (Etanercept) Added To Methotrexate In Comparison With Usual Treatment In Subjects With Moderate Rheumatoid Arthritis Disease Activity. - Extra
Wyeth Pharmaceuticals France0 个研究点目标入组 700 人开始时间: 2008年3月24日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 700
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1- Eighteen years of age or older.
- •2- Meet the 1987 ACR Revised Criteria for Rheumatoid Arthritis.
- •3- Active Rheumatoid Arthritis: evidence of clinical signs of joint inflammation / swelling at screening and randomization.
- •4- Documented evidence, confirmed by a blinded 3rd party assessor, of at least 1 erosion observed by X-ray (hands or feet) at randomization based on X-ray taken at the screening visit.
- •5- Plasma C-reactive protein level of at least 8.0 mg/L in sample taken at the screening visit.
- •6- Currently receiving optimized* treatment with MTX but with active disease as defined by a DAS28 score of >=3.2 and <5.1 at both the screening and randomization visits. The erythrocyte sedimentation rate (ESR) value at the screening visit will be used for the DAS 28 calculation at the randomization visit. Have received MTX orally, intramuscularly or SC for at least 4 months before screening with at least 2 months at the highest tolerated dose (not less than 12.5mg/week).
- •7- Have received MTX at stable dose for 28 days prior to the screening visit.
- •8- In the opinion of the investigator, suitable for continued treatment with MTX at a dose of 12.5 mg/week or greater, but no more than 25 mg/week.
- •9- Functional status Class I, II or III as defined by ACR Revised Criteria.
- •10- Onset of disease after 16 years of age.
- •11- In the opinion of the investigator, the subject will be able to comply with the requirements of the protocol, including ability to present for all required visits.
- •12- Subject is capable of understanding and signing an informed consent form.
- •13- Able and willing to self-inject study drug or have a designee who can do so.
- •14- Able and willing to take oral medication.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Previous treatment with ETN, infliximab, adalimumab, other TNF-a inhibitors, anakinra or other biological agents.
- •Receipt of any DMARD, other than MTX, within 28 days of the screening visit.
- •Unable to tolerate MTX at a minimum dose of 12.5 mg/week orally, intramuscularly or SC.
- •Known significant (in the opinion of the investigator) concurrent medical disease including:·
- •Cardiac failure.
- •History of or current pancytopenia or aplastic anemia.
- •Diagnosis of multiple sclerosis or other central or peripheral nervous system demyelinating diseases.
- •Current malignancy or an individual history of cancer (other than resected basal cell carcinoma of the skin) within 5 years of the screening visit. ·Active infection including known human immunodeficiency virus (HIV) infection and tuberculosis (TB).
- •Sepsis, or at risk of sepsis.
- •Subjects with signs of immunodeficiency.
- •Other current autoimmune connective tissue diseases.
- •Significant renal disease in the investigator’s opinion.
- •Clinically significant abnormal screening laboratory values in the investigators opinion (based on country-specific standard of care).
- •Females who are pregnant, breast feeding, or at risk of pregnancy and not using a medically acceptable form of contraception.
- •Use of any investigational treatment or device within 3 months (or 5 half lives of the treatment, whichever is longer) of the screening visit.
- •Concomitant oral corticosteroid >10 mg/day of prednisone or its equivalent at the point of screening (corticosteroid dose must be stable for at least four weeks prior to screening).
- •Intra-articular, intravenous, intramuscular or subcutaneous corticosteroid injection within 28 days of the screening visit.
- •Active alcoholism and/or substance abuse within one year of the screening visit.
- •Conditions requiring initiation of new drug therapy concurrent with entry into this study.
- •Receipt of any live viral or bacterial vaccines (attenuated vaccines) within 28 days prior to screening
研究者
相似试验
进行中（未招募）
不适用
Estudio para evaluar la tolerabilidad del dispositivo de inyección sin aguja para la administración de Fuzeon.Infección por el VIH, no especificadaMedDRA version: 14.1Level: LLTClassification code 10020441Term: Human immunodeficiency virus infection, unspecifiedSystem Organ Class: 10021881 - Infections and infestationsEUCTR2006-003821-10-ESRoche Farma, S.A.
进行中（未招募）
不适用
Estudio aleatorizado y abierto de la eficacia, seguridad y tolerabilidad de dosis repetidas de bevacizumab intravítreo en pacientes con edema macular uveíticoEdema macular uveíticoMedDRA version: 9Level: PTClassification code 10046851Term: UveitisMedDRA version: 9Level: PTClassification code 10025415Term: Macular oedemaEUCTR2009-010327-41-ESFundació Privada Clínic per a la Recerca Biomèdica
进行中（未招募）
不适用
Estudio abierto, aleatorizado y comparativo, para establecer la seguridad y eficacia de Bondronat i.v. (6 mg) en pacientes con cáncer de mama y metástasis óseas, que presentan dolor de moderado a grave”.Dolor en metástasis óseas de cáncer de mama.Classification code 10049038EUCTR2005-004760-23-ESRoche Farma, S.A.
进行中（未招募）
不适用
Estudio abierto, aleatorizado y controlado sobre las propiedades antiinflamatorias de sevelamer (Renagel®) en pacientes sometidos a hemodiálisis crónicaEnfermedad renal terminal (ESRD)EUCTR2005-004052-12-ESAsociación Científica para la investigación Nefrológica (ACINEF)
进行中（未招募）
1 期
Etude prospective, randomisée, en ouvert évaluant le bénéfice clinique sur les hypoglycémies après 6 mois de l’addition de la vildagliptine versus celle d’un autre antidiabétique oral, chez des patients âgés diabétiques de type 2, insuffisamment contrôlés par la metformine en monothérapie. - GLYCEMIADiabète de type IIMedDRA version: 12.1Level: LLTClassification code 10012601Term: Diabetes mellitusEUCTR2010-020460-38-FRovartis Pharma S.A.S400